(19)
(11) EP 4 005 604 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.07.2023 Bulletin 2023/29

(45) Mention of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: 22151242.9

(22) Date of filing: 26.09.2014
(51) International Patent Classification (IPC): 
A61K 49/00(2006.01)
A61K 9/00(2006.01)
 A61K 41/00(2020.01)
A61K 9/10(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0009; A61K 41/0028; A61K 49/223; A61K 9/1075; A61K 31/337

(54)

DELIVERY OF DRUGS

VERABREICHUNG VON ARZNEIMITTELN

ADMINISTRATION DE MÉDICAMENTS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 27.09.2013 NO 20131293

(43) Date of publication of application:
01.06.2022 Bulletin 2022/22

(62) Application number of the earlier application in accordance with Art. 76 EPC:
14847119.6 / 3049117

(73) Proprietor: EXACT THERAPEUTICS AS
0581 Oslo (NO)

(72) Inventors:
  • Healey, Andrew John
    1528 Moss (NO)
  • Kvåle, Svein
    1430 Ås (NO)
  • Sontum, Per Christian
    0259 Oslo (NO)

(74) Representative: Bryn Aarflot AS 
Patent Stortingsgata 8
0161 Oslo
0161 Oslo (NO)


(56) References cited: : 
WO-A1-99/53963
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).